<SEC-DOCUMENT>0001213900-13-003018.txt : 20130607
<SEC-HEADER>0001213900-13-003018.hdr.sgml : 20130607
<ACCEPTANCE-DATETIME>20130607105708
ACCESSION NUMBER:		0001213900-13-003018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130607
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130607
DATE AS OF CHANGE:		20130607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52446
		FILM NUMBER:		13899335

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k060713_actinium.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
    <title>f8k060713_actinium.htm</title>
    <!--Licensed to: icanbpo-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): June 7, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52446</font></div>
</td>
<td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52446</font></div>
</td>
</tr><tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">incorporation)</font></font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">501 Fifth Avenue, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10017</font></div>
</td>
</tr><tr>
<td valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code: <font style="DISPLAY: inline; FONT-WEIGHT: bold">(212) 300-2131</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="35%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>
</td>
</tr><tr>
<td nowrap valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="DISPLAY: inline; TEXT-DECORATION: underline">see</font> General Instruction A.2. below):</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 8.01.&#160;Other Events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc., a Delaware company, issued a press release on June 7, 2013 announcing the proceeds received from the exercise of its Series A Warrants. A copy of the press release is attached to this Form 8-K as Exhibit&#160;99.1.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01. Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">(d) Exhibits. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibit&#160;99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press release of Actinium Pharmaceuticals, Inc. dated June 7, 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: June 7, 2013</font></div>
</td>
<td align="left" colspan="2" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Sergio Traversa</font></div>
</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim President, Interim Chief Executive Officer, and Interim Chief Financial Officer</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k060713ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE OF ACTINIUM PHARMACEUTICALS, INC. DATED JUNE 7, 2013.
<TEXT>
<html>
<head>
    <title>f8k060713ex99i_actinium.htm</title>
    <!--Licensed to: icanbpo-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="img.jpg" alt=""></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Actinium Pharmaceuticals receives US $3,457,087 in proceeds from the exercise of 2,095,204 A-warrants</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #282726; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">New York, NY, June 7</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">,&#173;&#173;&#173;&#173;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> 2013</font> -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font>&#160;&#160;The warrants were exercised at US$ 1.65 per share<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> resulting in gross proceeds of US$ 3,457,087 for the Company.&#160;&#160;As of June 7, 2013 the total number of outstanding common stock is 15,825,394 shares.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #282726; FONT-SIZE: 10pt">&#8220;The proceeds from these exercised warrants will be used for the Companies clinical and preclinical programs and for general working capital.&#8221; said Sergio Traversa, Interim Chief Executive Officer of Actinium Pharmaceuticals.&#160;&#160;"This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> where they have made significant advances and already helped a number of patients," added Dragan Cicic, MD, Chief Medical Officer of Actinium Pharmaceuticals. &#160;"The Company intends to advance its programs into late phases of clinical trials and add new programs by the end of 2013."</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #282726; FONT-SIZE: 10pt">Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #282726; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Actinium Pharmaceuticals</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #282726; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For more information:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Visit our web site <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">www.actiniumpharmaceuticals.com</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>or</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contact:</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Segio Traversa, CEO</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals Inc.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">E-mail: </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">straversa@actiniumpharmaceuticals.com</font></font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><br>
Media:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dennis S. Dobson Jr.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel: (203) 258-0150</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">E</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">mail: </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">dsdobson@optonline.com</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">www.dobsonmediagroup.com</font></font></div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statement for Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #282726; FONT-SIZE: 10pt">This news release contains &#8220;forward-looking statements&#8221; as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.&#160;&#160;No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="#282726">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="#282726">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````P```#$!`@`0````3@``````
M``"CDP``Z`,``*.3``#H`P``4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`$<!
M7@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M*CEEC@C>:5TCBB5I)9)'5(XXT!9Y'=B%5%4$LS$``$D@`FO/?BY\6/`/P-^&
M_C'XL?$_Q%9^%O`O@71+K7O$.M7K'R[:SMEPD4$2!IKN_O;AHK+3K&W22ZOK
MZXM[2VCDFE13_"=^WK_P5N_:/_;/\1ZYX-\*>)]9^$7P0@U"?3M`^&?@R\NK
M+7/&UI<R^192^.M8L8X]8U?6;_\`=I%X9LKF/1+2246@L=0O'-V8E-1TM=]%
MMVZ]M?/J5&-]6[+;17;>FB6BTOJVTDN[:3_LG^*?_!1+]B7X+WS:7\1?VE/A
M9HNII.MM-IUMXCM];OK>9P2J7-KH0U*6WZ<F94VD$,`017,>"_\`@J'^P%X_
MU9]$\-_M2_"N74DBBE%OJ>N'01(LTOD1B&;6X-/@F<R=8XY2ZH#(P"`D?R-?
M`#_@BC^W-\;]$L/$C?#_`$'X1>'M9AMKF'4/BO>3^&M?N;>>T1OM;>$H+&]U
MZ-TE/F1C4K72'F9A,MJ$?=76_%;_`((*?MY?#/0KW7M%TSX=_&JTL4N;Z31?
M`6M):^)VCDA>.:TT[0O$6G:;:ZE,R+$Y2&^2YE9-EJI>6=9IYJFFBM_A;[=;
MKY.UMQVAV;Z7YDM5;6W*]+WMO=6:>C2_N=TC6-*U_3K75]#U*PUC2KZ%)[+4
M]+O+>_L+R%QE9K6\M9);>>)ARKQ2,I]:T&8*,G_/^>I]J_SCOV8/V^_VO/\`
M@GK\3+W1O"FI>(+;2/#GB9-)^)_[/OQ'M]0A\./%;WB_VMH[^'=0C74/`'B2
M)7F:#7M%M]-2&=HWOK?5+-S;2?U2_M$_\%B/!I_8%T;]IS]F.PN/%GBOQ]JL
M7P\\J6U34;3X&^.[G2YKN^_X6C"C;-)GT]8I#X<@U-(+3Q+=2:?);^=9W&'^
MAX4X<S;C/B+)^%LCHTZN;YYCJ.`P-.M5C0HNK5U<ZM:II3I4J:G5JNTIJG"7
MLX5)\L9>/Q#G67<,9)F?$.:U9TLLRC"5L;C*E.E*M5C1HQYFJ=*FG*I.;:A3
MBK7E)<S@G<T_^"J/_!4VQ_94L7^"GP2OM+U7]H77;2.YU'5;B6PNM%^%6D%!
M=)<ZS!-/Y<_B35X(VCTS2[A!#9V<DFJ7N[;:6UQ]F?\`!/\`_;)M/VP_@9X8
M\;:UH?\`PA7Q(.DQ7'BCPA<W%LDU]:1W$NF6_CKPY9?:&U&3P1XDU"SODT?4
M+RVMPUW:7UE&9EM%GE_A_P##.E:?+I7B3]K']I*;Q!XXM-;\1:UJ'AKPKJ.H
MR_\`"0_M+?$RUF6:>Q.I%$U'3?AUIE^ZW/Q,\6V#&"SL98_"6BR6^JW"O9]K
M^QI\7/VVOB;^W)X%\9_L\ZA<3?M`^)=0A35=+5/L_P`,+'X::7!:V>H>&/$6
MAV\<=CH_PQT#1UMK>PTN%$GTI%M6TJ==7E26?^A?'?(?"KPTX?R'PLX<PM+B
M'Q$RG%_VGQGQI3JRI_5\5B</&G7R.-*,YTZL9M8>I2P+M'*:.'I2JSEF68Y@
MH?B/@_G/B)QYGF=>(6>UYY)P+F>&C@.$N%:E*$IXC#4JJJ4LZJ5)*%2E*SK4
MY8F*?]HSKR5.*P6"PDI_Z'5%5+$7GV2U.H>0+XVT'VP6Q<VPNS$GVD6YE_>>
M0)MXAW_.8]I?YLU;K^7C^@PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*_F9_P""D7_!
M9']HK]D3]JOQG\#?AUX9^%6J>'O#VB^%M0LKCQ/I6M7>KM+KFEI?W+W=S:>)
M+*W\N.02QQQ)8(5C"N7<YV_TS5_)#_P5=_;P^._P._;/\<_#KP)\/?@AKWAO
M3?#O@VZBU/QI\$/#GC;Q%<W.HZ.EU+%<Z]J$;7%Q;Q.72!9"1;JPB3`5J_H_
MZ+W#&7\6>(>/RW,N#LEXWP]+A?,,6LISW-IY/@Z52EF&54XXV.*IX#,)3K4H
MUITHT?81YH5ZDO:1Y+2_$O'O/\?PYP5A\=E_$V:<*5YY[@L,\TRC*:>=8J5.
MIAL=-X66#J8C#)4JTJ<92K1FY0G3A%1]]RC^8_[9G_!5K]H+]N;X<Z;\*/BE
MHW@W2/!&GZ[#XENK'P)::UI8UW4-,@<62ZN]SK]\M[:V,CRSVEHQA$=VRW+)
M*UO`#\J?LT_M!67[+WQ7T_XP>'_AG\./''B/PU"TWA23XCV5_KFG^'M3E$"1
M^(--TB/5;&%=>C@B6"&XO9K^+2FFEN+6**]V7(;^T7\>?B7^T3XKLO'GCGPM
MX2\/ZQHWAVW\,Q_\*W\#V?@'19K9+ZZU."2[TW1K=;"YO?M-W+;MJ<@%PR1Q
M0"38D=>X?`_]O#X[_`[P#8_#SP'X(^"VJZ+IMU>WTNH>-?@_H7Q$\1/=:G<F
M\NQ<>)-7CGU"XCDF#FVLW?R+':UK:KM5%']_R\$.%%&,W]'7PQ4)77.N/<5.
M=_<:;<N#$XOE27NUI<KTLW)-_P`9?\15XFYW"7C9XAN4;I17`^'A%M<M_P!U
M3XC?,I*5ES85*[YI--11]_1_\'#G[9$\NZ/PM\$A$L<LLJKX9UDA(!`WEGS)
M/$_)\XQLTA8*8W)$1\ME;:^'?_!?W]LGQ5\1O`/A;4])^""Z=XE\:>&?#U_#
M9^%]56Z:SUO7=-TR:6*=_$TIAF\BZF:(^40LH3AQP/D,?\%2_P!K,Q_Z/\.O
MV;E\P`S-'^S1X*&(`RLDDENUH)&9CEA&QWQ_*[1`JU=G\+/^"D_[5.N?$KX>
M:5>^"/V?[:RU3QWX*L;R6W_9J\#:?>BSU+Q%IEI=O;746FM<6ES;PS2RK/"H
MFM7,$R.&`!XL=X,\+T,#CJG_`!+_`.&='DP==QJKC3$5)TW&C-QJPC+A#6I&
M5I12:;M'WHZLZ\'XG\2RQN#IS\:>/JO/BL-%TGP11IQJJ56%Z52;SAJG":?+
M*:46E=R4EJ?T`_\`!6K_`()5:#^VMX)F^,WPFL-.T']J'P5H+26,T:06=I\6
M=$L[9I3X(\0W)79%JPB+KX5UVXWFSO!;Z?>RII<[RVO\@'[.7Q\\9_L=^//B
M)X<U_P"'J^./`OB_2[[X<_'SX`^-WN]%T;Q-9Z;+/:?8=72V26^LO&'A74&>
M?1?$,4,]SI<K[+99K2=HV_T._P!HS]I;X2_LH_!KQ#\:OC-XILO#7A3P]I^^
M"-R7U3Q)K<D#OIGACPSI<2O=ZOKVL7*BUL-/LXI)`&:><PV=O<3Q?YW/[5W[
M0?B_]N/]J;Q)\2['X7KI_B[XCZG9Z9H7@CP#H$]WK5Q;QEK3P]8/9Z-&+SQ1
MXDDL+9SJ>KPV4][<W.]976WM8D7_`!_IXBO@\50Q6$KU<+BL-6AB,/7P]2=&
MOA\10J1G2KT*M.4*E*K3G%2IU824HSC&<6FKO_2V=&EB*$Z.(I0KX>O3G1JT
MJT(SI5J56/)5I5:<U*,Z<X3<9PDG%J3C)-2(KOQ1\:OVT/C?X3\%>%O!]OJ?
MBWQ%#8>`O@Y\+O`.DC3_``U\//"EM<&YTSPGH%M+-FR\.:1:>;=>(]<U"X:2
MY\O4O$FMW4MY<3A_[I/^":/_``3G\`?L!_"1],@-GXF^-/CJ&QU+XL_$$VZ"
M2]U!$,\?A?P^[^9-8>$M#N)IDL;2.0+?W(EU2\5[B9%B_B]_X)X_MJ>(?^"?
M?[2$?Q$U;P)IGB3PC=23>`OB5H%_96Q\;:?H45Y%;:E?^$+V]634=#\4:5<1
MR7%]HCO%;ZK;VESH]_'%<1Q36_\`H3_"/XM_#OXY?#OPO\5?A7XITWQCX#\9
M:9!JV@:]I4OF6]S;SH"T,T9`EM+ZUDW6U]87*1W-G=12P3QI(A%*I6JXG$5\
M3B:U7$8FO5J5ZU:O4E5K5ZM6;J5:]:K.4IU:U2I*4ZE24G*<VYR;E-R93I0H
M4J5&C3A2HT:<*5*E2A&G3I4X0C&G3A3A&,84X0C&-.$8J$8I**LCTFBBB@H*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"L.]\,>&]2N'N]0\/Z)?W4@59+F\TJQNKAP@
MP@::>!Y&"#A06.T<#`K<HJX5*E)\U.<Z<K6YH2E!V=FU>+3LVD[;:(F48R5I
M1C))W2DDTFMG9WU7<_+G_@J5^P4W[9/[+>O^!_AA):^$/BGX0U"V\=_#W^S3
M'H>E^(]<T5)&?POK[V2P(]MK=D]Q::?>7*RQZ5JS65\4\N.6OXB_V;_VE_CK
M_P`$_OVCYO$5GX=O9/%7A2[O?"OQ9^$?Q)A(TKQ!IOVCS;[PWXBM+I9'L-0L
MYX([S2M<L[87%I+'%>6<M[8W<]O<?Z776OS9_;G_`."6/[+'[=]I_:OQ$\,S
M>$?BG:6GV;2?BYX&6UTGQ<JPH5LK7Q$?(:T\7:99,Q:UL==BN'M`T@L;BTWL
M2W7Q#ES>WKN7?VL^9.^C4KWNO6WSO<Y():4X?^`QZVO?371;?J?*G[/O_!:S
M_@G!\8="T.;Q_)IGP%\7ZA9"34O#WQ#\&Q?V3:7\2(+JVT_Q;I>E76D:E;;B
MTEI.WV26:U*23V\$A>%/3OBM_P`%>O\`@F)\*]-N=0T[XC^$/B5K=K')+:>'
M/A=X//B/5[B:&..>!([D:9::;9B4NODW%Q?Q1(Z2993"^W\2OBG_`,&VW[3N
MBW)/PB^.GPK^(^CP.#96GCZ'Q/X%U:TM]H4V]H--M/%6EQ3,[O*UQ;2Z="`J
MJMJ9#Y@Y_P`$_P#!N-^V/KU[IS^.OBE\"_AQI<DKIJ<6AZCXL\=:G;1*K(MU
M:PMX<\.V5Y/..3'<:C#'`LA*_.IW-XW&.R^L8AI[IU:MM?6=MM'=?@+V-#?V
M-)O=>Y%*ZMKK'FZ=&GZ;'Y_?\%!O^"@?Q1_X*)?%73=9O-.U/PK\._#MPVE_
M"KX/:9=2:R=.GNRMB^I:J]E\GB#QYXE>Z2WC2'36M[%1;Z-IHG/G7%U]\Z7_
M`,$]/VC_`/@GO^Q9JW[7.D>#(O$/[2'CNV_LK7-:NF9M:_92^#6M6<C7VK^&
M=%2.YFE^(/B3[6MGXI\2?:UD\":<3;Z9&7-_>2?NW^PQ_P`$8_V:?V.=:TKX
MCZN;GXT_&;1YI+K1O''B^PMX-+\*7<F]/M7A#PNDES9:;J,<)5(]9NY;W5HF
MWR6US;O(S']>K^PL]4L;O3=1M+:_T^_MIK.^L;R"*ZL[RTN8VAN;6[MIU>&X
MMIX7>*:&5'CEC9D=64D'W>"\\PG"_%.0<0YADN!XCP>3YGA<?B<CS)S^IYE3
MH5%.5"NXO1IKGI>TA6H*M"#Q&'Q&']IAJGC\2Y5B<^R#-\GP>:8K),3F67XC
M!X?-<"HK$X"=:#C&M14K6:T4^25.KR.3I5J-;DJP_P`UWQ)X:M?VM])D\5:6
M9D_:C\,Z/<:AXHTV&4V5Q^TAX;TFP-Q>>,-)B7RTO/C9X9TRWG?7K'3VBNOB
M;H]K-K-K!-XJMK^/5?JS_@D__P`%(_'/["?Q`M_#?B^;5_$_[,?Q*UL0>+?!
M\!.H:GX.\0S216\/CSP/IUS,E\)&,R1^(]%T]'CUNVB\Q+,:S!#-+]/?\%9?
M^"8NO_L>^.'_`&D?V>]/U"P^!&I:[::H[>'Y)(-3^!OBZ34H+FPB@O+?_B96
M?A2XO@K>&M421CH=\8].NI51K.1OT-_X)<_\$W_#?Q4UKPG^WA^TG\)8/#GC
M>^CM]7\'_#_4;2R_X1OQ%XHM27A^/UUX8:TA?P]JWB=9_ML?AV<W%@VLV[>,
MK:&REU2.TA_HKQ_\/N!<9DF4^.'A9F67T.%.+\<\+FO"]2OAL+C\CXCJTWB,
M9A\%@/:\RIQESRS#+,.IK+:CI8K!NKDV.PSPGXGX.<9\88;-\R\*?$/`XVMQ
M%PS@_;X#B*%"M6P6=Y%3J1P^&Q.)Q/)R*NTX1P^+J2OC%&=*NXX_#5HU?Z2=
M-O[;5=.L-4LVD:SU*RM;^U:6&6WE:VO(([B!I()D2:&0Q2(7AE1)8VRDB*ZD
M"[2!0O3I@#'H!TQZ?YQ2U_*9_0X4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`",=HSP/KP/?)[<9YK\6/"'_``6M^"'C']M)/V2+#P5KL&FWWQ"U
M'X8:+\6Y]5L#X=U7Q5IXDLE@BTY(C<QV^H:_;SZ18R-<%I=]E=E!#=+M^P?^
M"D?[2%I^RO\`L;?&;XJ&\2T\0'P])X/\#(9%CFO/''C%7T3P_!;$LA,L$MQ-
MJ4FPF1+:PN)D5FBP?XV=7UOP!HW[`/PEM/#'@[XYZ+^U-X$^/NI_'_Q'X[D^
M#?BB/X>W`N9[9;2XB\?HD=M<:;H.C>'/".KQ7=W;212ZI'?("4(NCG.33]WI
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MO=8:Y79=-%H=Z/LZ6[,A\DL<2#%V;X\?&%?VM+?X#0?LX^*9O@X?`Z^)KS]I
M)M=TQ/"D.ORP/-#X3@T$J=4N+S>GD37098HG=#M93FOY_OCQ^R'\`O$__!=7
MX9_"O7O"UU=>$_B?\-]6^+WC'34\1:W9OJGCM=+\8:F=5M[F&_6ZM+>6^T.P
MDFTRSEBLV6+RS`\<DH/NMQ]FT_\`X.,=(TRS>1(XOV6;"T2U\R3RX;:U\)S"
M%%03$/'L6/#21']XK8;<#F%.77_GXH^Z_O3]W96OT;3LVK,.5?=#FUZ]GHU9
MNZMT\FW8_HMU#6-)TFRO-2U75-.TS3M/B:>_O]0OK:SLK&%`2\UY=7,L<%M$
M@!+232(B@$DC!KFO&?BJ^T;X>>*_&7@S1QX]U72?"&M^(O#'A[2;ZW!\8:C8
M:1<ZCI&BZ=J*F6V5M=N8K>RM;L&2%3=1R_,G7^67]BO]CGX4_MI_ML?\%-O#
M'QTOO&>L?#SP9\5M/F;X=Z/XNU;0/#WB77M>\7?$6/3O$NNPZ1>0/>7/ANRT
M6_T_3K&^62)%UV[N?F5T0;W_``39FU3PA^SA_P`%?_@GIOB+7+WP)\)[3XXZ
M+\/]%U._EO[?0[*PT+XH^'TGL)9BC6LU_9Z#IDFH111PV\UY#)=(#)++([51
MM7MRIQD[WNTXJ[TMMJK/7S6UVX)-J[;35[I6L[::-ZKKKKM96;/Z)/V7?C!\
M2?C/\&]#^(?QC^"VL_L[^-=1OM7M=3^&OB?6++5]1TBWL+^6UL+N74[-8;29
M-4MECO8D10T2R>6V74U]#O<VT<0GDN((X6QMF>6-(FW#*XD9@AR`2,'D#(K^
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M>\TZ[%K>RB&]MVDGAD=1'&)&$T?D?Q9_8`_9U^'W_!7CX'?LB^!]`\;^%?@-
M\?OAO>77Q6\/Z)X^URQA\76VC>&/'WBV\\,Z[J`NY-;U71/$>K^"]"NM8L)K
MI8I9UN)%D#74^7SN[2BGLOBZM)I;-=7K=;=0BHM:\VU]+:*^MT[-W6RNM=]-
MOZZO#WB?PUXMT_\`M;PIXAT/Q-I1FFMAJ?A[5K#6M/-Q;MLGM_MFFW%S;>="
M_P`LT7F>9&WRNJGBN)^-_P`1I?A!\'OB=\4X=(&OR_#SP+XH\91Z&UV+`:N_
MAW1[O5%TXWS13+9_:S;"#[0T,HBW^88V"[3_`#L_\$]?AWX;_98_X+*?M6?L
MN_!6[U?PW\&+/X7)KS?#^;4KZ]TC[=)8>`]>TB^2.Y,D+WFCGQ#J6G6MXSMJ
M)T^1H+B:6(*!^['[;*._[(/[321H\DC?`WXG*B1@M(['PAJNU4"\EB<`*`2Q
MP,'H3FYHR:T:YEWU2WM^6_Z!:*G'?E;COV=M--]_^`?CQ\*O^"S_`.UG\;OA
M^?BE\)O^"9?Q%^(W@6UN=3TW4]>\(?$*PU&&UUC1;6"YU33K>U?08+^_FL_M
M,,<B6MI)*S2+]GCN"<'ZF\&?\%=_AQ\3OV"_C7^V;\/OA_JM[KWP*LYH?&GP
M>US5[?2]3MO$$<]C';V8UV.VNHCI&HQ7HN;#5OL&9(XI4DM8YHY(D_%+_@E%
M9_\`!6G6_P!D);+]BW4OV:=`^#5U\0_'%C>7GQ-GO8O'6F>,I[72!XBNH;>W
MT'5;>"RBCN-,GL`[/<1-'-YE@&VQM]B>/O\`@GB?V`O^".W[;GA?Q1XUM/B!
M\3?B5H">,/'FO:9#>#P[;7=IJNCVND:%H(U2.#4=1LM-@#>;J6HVME=ZM=SS
MSM8649CMH\TY\MTY/W'?FMO;=66KTTU6^JVM3<;VM&]U9*_=7YOEV\];G[5_
MLM_M>^!_V@?@1\"_BQXFU+P9\,O%/QO\'Z=XJT?X<:IXXT:;60=2N[BSAL])
M2^?2M0UU7G@,,5Q::8!--NBC0L,5]7ZIJVEZ)I]YJ^LZEI^D:5I\$EU?ZGJE
MY;V&GV-K$I:6XO+V[EAMK:"-06DFFE2-%!9F`!K^+[XA?\$]?V:D_P""(O@[
M]K>X\/:O>_M`V_@SP%XL3XBWFO:O<WVGVVI^.K30#X7T?3Y;J>PT/PUIFEZ@
MUOING:5:P&QE@6>"99))F?Z&_;,^*7@WXO?L0?\`!*7X<?&27X^?&GXG_&7P
MYX)\1:9\&/ASXR\-^"M&^,>IZ=IGAO1C?_&/Q;XCLKVY;3X[J]BL=-M]/LY[
MN\U'5]1U.[FL/L":I;7SM*S6O*FG=ZWY5KHM;O6PE!2:LVM6I7LEHKZ.[6MF
MM;ZVWN?U/^&/'G@;QM'++X-\9^$_%T4$5O//+X8\1:/KT<,-TK-:S2OI5Y=K
M'%<JCM;R.0DRHQC9@I(S[_XI_#'2T\02ZG\1O`>G1^$WMH_%4E_XO\/V:>&9
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M0_`-CJ$VD7OCCP=::M;:*_B.YTNZ\3:+;ZA!X>C@:YDUZ:RFO4N8M&2W5KAM
M4DB6Q6!6E:<1@L,^#XM?"NZ\-W/C*V^)OP^N/"%G=?8+OQ7!XS\.3>&[6^W*
MGV.YUR/4FTR"ZWNB_9I;I9MSJNS+#/\`,/\`'7]G/X2_'3_@OMI'P.^)?A^Y
MUSX:7'[)OA"WUCPU'JNH:;!XET7PQX;U9-.\/^(KK3KJTU"_T%Y5MYK[3#/]
MGU"6T@^U%D4QOYI^QK_P3\_9J\;_`/!33]NK]DKQ=X5U76?V=OA1H;^+_!/P
MNDU_6K#PM:^)-3U31M`M=:O;;3KFQ&KZMX;TG6]0LM$O]0-S>645VA^T2!0"
M>T=[63?,XK6RNK;Z-K1ZZ-=+W$U!)?%?E4G=QM=VVLM+-VUO\^O]=VAZ]HGB
M72;/7O#NLZ3K^B:C%Y^GZSHFHV>JZ3?P!FC\ZRU&PFN+2ZBWHZ>9#,Z!E9<Y
M4UR-G\7OA-J&OMX4L/BA\.[[Q2MW)8-X:L_&WAJYU];^%F26R;1H=3?41=Q.
MK));&W\Y&5E9`5(K^2S_`()V?$GPA\"?V#?^"K/@?Q_XV^)F@_!?X5^/]2\$
M^'I?A;?QP>/M)D\6:IJWP^M;+X?OJ(ATO0O$'B?58-'M&NV>'3(+^^GU:ZFA
M)GEK\^?VH?@'IWPZ_8=^%WQ[\!_L<>#?V=-&U3Q-HNM_#GX^>+/VD?\`A,_V
MDOB/)=F[O;6:+P9H.A:/H=O]L0C4;W587LKO2=.L+.Y6W:>1G*]HVHM+HG):
MW5W;HK='N^UKW5WR1OO*UVEHKZ)-^MK[V2LKZ7LO[[/'J^!&\(Z\OQ+D\+IX
M&FL'@\2GQI-I4'A9M.F=(F369-:=-+6TDE:),WCB,R&,`[]E)X)\:^`?&NEF
M[^'GB_PAXOT:P:*Q-UX,U_1=?TRR:.",Q6;3Z)=7=K;,D!C:.W+H5A*%4"$5
M_+1^WUX@U/\`:`_;$_X)3?LY_'[Q=<Z;^S=\3OAS\-O%/Q`T2YU._L=&\>^+
M-?TO?>VVMW]K-9VD[W=]9Z5H=KJ,SXTU]=GN(A;S7$<H^Y?A;^S!^PC^R;^V
MYXKN/V2OC9J'@7XY77P;UZ_N?V//!GB*/5O`OBN"R\/:C?:;JVMZ;+;:C>+<
MI=PVM_:M=:P)-/N9"]L(8=0EAGU=>HXJESR=&%24XTW4ER*K4A34ZD*3]Q5)
MPA3C*22E.,()MJ,4L_904G4Y5[24%&5115^2+<H0E*W.XQ<YM:\JE*5E=MO]
MF_%'QD^$7@?6;;PYXT^*GPW\(^(;U(I+/0?$_CCPSH&LW4<[F*"2VTS5M4L[
MV=)Y08X6C@997#)&68$5U/B'Q;X4\):._B'Q7XF\/>&=`C,(DUSQ#K6FZ+H\
M9N#MMP^IZE<VUDAG8@0AIP92<)N-?P;_`+(/P.\;_MB_#3]I[XN^/OV:/@E^
MTMXX\3^,_%[^,_C3\:?VK9OA-X[^'.JS6"7@>T\.2^%]4LGTS1;N[N+C3]1U
M&633K6.P&@6UK%9:>D9^M/CGX+^,7A+_`(-WO%G@OXX^.OA[\3IO#7QOT33/
M`^N_#_QW8?%/P[%\.K7Q9IZZ-H-SXGM;5+*:ZTC57UG37L0)$TVS2SLHY?DC
MC7)56[^ZMKJS]-&[+OTO9Z,OD6C3;3:[:I]8ZM:V;2NWU=KJ_P#89K/CCP7X
M=T.U\3^(/%_A?0O#5^;(6/B'6=?TG3-#O#J48FTX6NK7MW!87!OXB);+R;A_
MM49#P>8IS7P7^U]_P4Q^!_['7Q/^`'PK\:6-_P"*]<^/NOQ:)87/A;7O"OV?
MP3:W-_H%E8^(?&,.HZO:W5AH-^FO)>VFHK$;>:SL+Z9)"D6:_#O_`(+'>+O`
M>O\`_!'']@?0=(\4:!JFKW3?LRWND:-IFHZ=?W-U;Z!\%;FWU6X:RCN',=IH
MSRQQWLTBC[%</%!M,SA#QG_!8CX#?!JY^.O_``2>\7:CX0TAO$'QZNOAU\/O
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MQ1^;+,LQC`FD#R>8/.M;^&OPR_;9_P""\_[17PG_`&V[>3Q5X`^$GP[>S^$?
MPT\4ZY?Z/X/M-(M-#\)7>E7NG"#5].'VG7X-<UKQ3?\`D1@ZE+<PI--*NDI'
M&<[3?=R26NB;26EEM>[O=_H5RQ=M'9)MVM=]>KW2;NTM;)+5Z?UD>&O%7AGQ
MGHUIXC\(>(M!\5>'M11I-/U[PWK&GZ[HU_&CLCR6>J:7<75C<HCJ49H)Y`K@
MJ3D8KA%^/?P-;Q.O@E?C1\)V\92:@NDIX2'Q$\('Q,^JO+Y$>EKH0UDZFVHO
M*#$EB+7[4T@*"$L"H_GX^#7A7_@GU^Q3\*_^"FL'P"_:]^,'C7X8>'_"NLWW
MQ4^"7PZUVQN'^`NHZA>ZMHMM%\*?$9TZU33?$>J7,]QX?M]2O-:OC*ME;WEY
M<R-I_P!HK\&?C[^SYX>A_P""=&C?M&_#O]B'X5_`OX=>(_$%EJ_P^_:&^)?[
M2-[X_P#VL?B++J6OW4=J\'A7P_X=TOPX6N;DSF:_NKF'4],T[3OMJ6GVYA?3
M-U&K:)Z7=G?K;1KIOOVVT8*"ZJ6\5;1-72<E;5[O1V2:UOT7]?W_``4$_P""
MA^N_L3_%O]C?X<:5\+])^(%E^U'\2=1\!:IJVH>*;CP_=>$([35O!&FPZAI]
MG#I.I1ZS),OBR>5[>:>Q5&L(HQ*?M):/]$/''Q-^'/PRL8=4^(_C[P7X!TVX
M=H[>_P#&?B?1?#-I<R*4#1V\^LWUE'/(ID7<L3.4#J6`S7\J7_!2?Q'JGB.3
M_@@#KVMW]QJNN^(+SP=J.K:E?2RW=QJ5U=6G[/D^HWE]>7$374UW<7+"ZN)Y
MGB:XG\QIG=V4'K/^"GW[+_Q%^*7_``4RT[XG?#_3/V8OVT-2T#X3^%=,B_8A
M^,'Q0&A>,?"=HL,T>L:[H_@Z_P!9\/Z3<6GB*WOH]>MM0AUI+_[6SM>Z%J=M
M#83**3O)V;NX)+2RO&_EUWU$DFDG96YM4G=ZKXG9M;[V=E:ZMJOZF/"_B_PI
MXWTF'7_!?B?P[XOT&X:2.#6_"^M:;K^DSRPMMECAU'2KJ[LY'B;*R(DS-&P*
MN`:Z*OYB_P#@AG\3?@-X+^-?[:'P0TGX"?$S]D_XM:1INB_%#XK?"CQ+\3(O
M'GP<\'Z9X;U&[T:]N/!C7%IIMYX1O()?$EL=6AOX]534M)MK&9==E&E/;0_T
M7_#?XN_"_P",.D76O_"KQ_X1^(>B6-^=,O=6\':]IWB"PM-0$,=P;*XN=-N+
MB*&Z$$T4Q@=A((I4?&UE)N,KI-Z-]-=UO:Z5Q2BTVU=Q7+[UM$Y):-[7O=+:
M]MKGP/\`\%5_^"A>I_\`!-_X%^"OC'I?PWTGXGR^*_BCI/P\FT35O%4_A5+*
M#4]#U[5SJD%S;:/K4UW)"^CI`]L+9%6.X,[RJ(]K??NF?$CPL^E>";CQ!X@\
M.>&]9\<:/I6HZ/H6J:]IME?ZC<ZA86]Y)9Z1;7L]M=ZHUNTQB_T6"1VVY**>
M*_GV_P"#G,I'^QI\$IC')(5_:9\,1%8=OF-!/X+\;)/&@;Y274*3OQ%L5_,9
M1@'QG_@K!\-/"WQG_;C_`."-_P`*O&2:HOAKX@PVOAK7WTG4FTB^&B:AJ'A<
M:C:V.J64B:G876H6ZR::T]@\3"UNK@"5/O">9ISW=G%)>J5VK*]M?-7ZJXU%
M-0TW<DVM]+?+3I\]>W].?A7XI_#/QWJ.JZ1X(^(?@;QCJFA2/%K>F^%_%F@Z
M_J&D21M&CIJ5GI5_=7%D4DECC87,<>V214.&(!I_$#XP_"?X3Q:?/\4/B=\/
M?AS;ZI*8=-F\=>,O#WA--0E4@/'8MKNHV`NW0LN\0>9LW`OM!&?YD/B7^S5\
M(_V$_P#@M_\`\$^M#_95\):?\(_"7QB^'_B'2O'WAC0;F[FTO4X!>^)=,N!]
MDU"[N9D&I6]O9O=2%Y5>]LX+M/*N(09/)O@I\%OV?_V\_P#@L?\`\%(M(_;Y
M%CXX/P4UG6?"_P`$O`OC;Q'?>']+TGP/HWB";2(KW1;>.]TJ6.'3_#46D:H6
MLYQ:79UZ76K@7?VQ95.?9:7<N7K:]D_+1WT_I`HQ;O>3CRWLK<SVTV:6Z>SL
MK^I_7UH>O:)XGTJRUWPWK.E>(-#U.!+K3=9T34;/5M*U&UDYCN;'4;":XL[N
MW?!V2P32(P&0QK6K\4?^"2G@;]BO]GOPY^U!X3_9,_:YU[XT?"'PS\0+#5O$
MWACQ9JNGMX$^`6L7(U^.YTGPOXA;2=)LUL=9MK.)]3,FHWD,AT:RU:1TN-3G
MNKW]A_"'C3PIX_\`#NG>+O!'B+1?%GA?6$FDTKQ!X?U&VU;1]12WN)K2=[/4
M+)YK:X6&ZMY[>1HI&59HI$SE3BXM25].NS3V?=?UJ3*-F[7MIJU9ZJZNOR[K
M6R/G#]KW]BWX._MM^$?!?@;XUS^,SX9\#^-[/Q]8Z9X2\1)H,&K:Q9:=?Z7!
M:^(4DT_4$U/2A;:E=,+4)!+'.4FAN8G4$^[>)OA=X&\7_#;6_A+KF@65SX#\
M0^$+WP+J6B+%&D+^&[_2I-%FLHB48Q,EA(4@F`+PR*DJDN@-%%%EO97>C=MU
MV)^_RU>GIV^1\<_#W_@F5^RSX!_9@\4_L@7.B^+/B%\$?%VMWGB*_P!%^(WB
MB77M5L-8NFMI4OM!UBPL]&GT2XLKNUBU"QGT](9H+XRS&2032(WC'PE_X(K_
M`+&7PJ^(/@3XBW4GQE^+&H_"R]M]2^&'A_XQ?%#4/&/@OP%J-E?)J6G7GA_P
MO!8:/IZOIE[%!<Z=;Z@+ZQM)[6TN(;1;BV@E0HHLGT7W+^K>6P[ON_/5Z[;Z
MZ[+<]I_:?_X)H_LV?M8?%3PA\;O'LOQ/\)_%3P9IUGHVG^-/A7\1-7\#ZK>Z
M+87<]Y::5J?V>.]MI+>&6[O$$]E!8W[P7<]O+>20E$3N;;]A/X%6O[6UI^VJ
MB^-)/C;8_#^S^&D%Q/XHEF\+'PW9:;_9432Z`]IB;5&M/];J$EZTDDN9-H+,
M"44<L=[*^][+=;/U71]-;;B[:O166KVVMOMHKK9V5S6_9^_8J^"'[-'Q,^._
MQ:^&%KXIM_&'[1NOZ=XD^)4FN^);O6M,N-3TN_\`$&HVK:)IDT<<&C0BX\2Z
MIYD5OO$B-`K,?)!;G/A/_P`$_?V;_@Q9_M):;X)T3Q1%IG[5M_XEU#XNV.K>
M,-9U5+N3Q?'KL>OP>'[JXE&H^'K6\/B35Y4AL[T_9)KA'M&@$,:J4466FBTT
M6BT3W2]0N^[^]ZVVOKK\R]\/?V"/V:?AS^RM?_L8Z9X0U/6_@#J=IK]G?>&?
M%/B36-9U2>+Q'J<NL7K_`/"2FYM]:AN;?49?M6FWEO=Q7>G2Q0-;3HT2FOBK
M2/\`@@M^P!8>%-8\&ZSI7QG\9Z+>S(V@1^+/C+XKO7\`6HU!=1GL/`::>VF6
MFA1ZA*@AU2]DM;W5]1M6E@NM2D2XN/-**.6+WBGI;5)V79::;#N^[N]W=WWO
MOO>^M][Z[GVE\5_V"?V<_C1XD_9L\5^.M!\27.L_LG")?@S+I?B_7-(M])6%
MO"CQIK5M97*1^(T#>"]!RFJB96$-P&!^U3;M[Q/^Q=\#/%_[5'@']LG6M,\2
MO\</AMX<O?"GAC5+3Q9K5EX<31K[3==TJ:'4_"MO<)I&JRK:>(M3\F:]AD>&
M9X9XRLL$;`HHLNRW3V6ZV?JK*W85WW>UMV].WIY$'A;]B/\`9_\`!O[4WC;]
MLC0=!\06WQU^(6A-X=\4:W-XP\176@7FF/I^@:64@\(W%_)X?LY_L?AK28UN
M+:QCF0Q3,KJUS,7^A/'O@SPW\3O!'BWX>^*H;B[\,>--`U;PMX@MK.\N]-NY
M](UJRFT_4(;;4+*2"\LIY+:XE6*ZM94G@<B2)U=5(**+):))+M8+O>^JV?IM
M]QXC^RM^RG\#?V*?AA/\'_@3I>NZ%X(N/%>M^-9K/Q#XH\0^,M0;7_$$.GP:
MG<?VOXAN]0U`021:79B*T$XMX"CM%&K2R%N]^-/PG^&?[1_PN\;?!+XG6-WK
MG@/X@:.^A^)M+L-2U?0+VYL'FBN`+76-)FLM1L)XYX(I([BTNH949/O%202B
MDW;E22L]+6Z:?YAY]>]]>G7?HON/*-2_8=_9VU;]E"Q_8IO_``SKD_[/VG^'
M])\,6OAP^,?$Z:XFDZ)JUOK>G1GQA'J:>)7N(=1M89GNGU%IYE4Q2NT;,I\J
M^+O_``2V_8[^-GPC^!_P;\9>"?$]OH'[.&F6FC?!?Q)X:^('B_P_\0?!&FVE
MM:6OV2U\:6.J#5]3BN4L+":[76Y-2$MY96U\OEW<2S`HIM)[I/U28[O=-I[W
M3:U[Z/?SW,/X=_\`!)/]B?X6?$_X8_&KP;X)\=VGQ9^%.H7.J:'\0=4^,'Q/
M\1^)M=O[R.^@NKCQQ?\`B'Q1J9\8"2RU&\TR*#6$GM;+2I5TVP@M;.**)/?O
M@]^Q;\`?@3\:_C-^T'\./#NMZ7\4/CY)#)\3-7O_`!=XEUO3M6>WOY-2B.GZ
M#JNI76CZ'MNI78_V3:6NZ/;$V8U5044<L=/=6FVBT]/N7W`VWNVWU;;;?75O
M5ZZ^HZ;]B[]G^?\`:OB_;7E\,:NW[0L/@>+X=Q^*?^$M\3#1AX5AAFMTLO\`
MA#QJ@\+FX\JXD5M0.EF^8E29_E4"S\._V.?@+\*_VA/BU^U%X*\,ZKIOQD^-
MVE6^C?$37KCQ9XGU+2M4L+6\L;^)+'POJ&JW'AW1)3<Z=9O)<:1IMG/*(=LK
MNK,"44679;WVZ]_46^[;^;^[T\MK:;'EG@?_`()G?L:^`?`/Q^^%^D_"VYU+
MP'^T[J<VL?&7PYXF\9^,_$=KXDU&6[O-06ZL)M4UZ>\\,36NH7LM_8R>&;C2
M9+"^CMKRR>"YMH)4\"3_`((=_P#!.N?POJ'A'7OAAXZ\7Z5<P6UGI+>+?C5\
M6=:O/!>GP71NYK#P!/+XM1?!4&IOY<.LS>'HK&^U>TABM-0NY[=3&Q11RQ_E
MC;M96^ZP[NS5Y)/>S:OZV:N?2WQI_P""=G[)/[0_PF^&_P`&_C%\,G\:^&/A
M#H6E^'?AMK-[XG\46?CWPEIND6%EIEJFG^/M,U>R\4R2RV.GVL%])>ZE=?V@
M8DN+U9[I5G6+]E;_`()R_L@_L9:SX@\4?`7X6MH7C'Q1:G3M9\;>)O%?B[Q_
MXPFTDR1S?V+:^(/&VMZ[?Z;I!FBCFEL--DM8;F2.)KH3^1"(RBBRO>ROZ+^D
M+775ZN[5W9OTO8\1^+G_``1A_P"">_QH^(7B#XF^)O@]K&A>)/%]]<:GXS@^
M'GQ(^(/P]\.^+M0O)_M-_>ZYX8\*>(M-T2:YU&XS/J$]K96DMW</-<S,UQ<7
M$LOUJ_[&W[,3_LZR?LF#X->#XOV=Y=&.AO\`#""VNH-&^QM<_;FN!=PW::PN
MKMJ'_$R.O#41K3:E_I[7YNB9244*,5M%+T27;_)?<NP=$KNRO97=E?>RV7R/
MA'3?^"#7_!,?3?#6L>%C\#->U*TUK4M(U&;4=9^+GQ6U37]/CT2>6YLM(T'6
MKKQ>]]X?T)YY1)J&DZ/)9VNJ^3:KJ2W4=M$B_77[2G_!/[]E?]KCP?\`#KP3
M\=?AY=>)])^$H1?AW>:7XO\`&'A+Q!X7C73K329(K+Q!X6US2=5EANK&PLXK
MJ&\N;F.>2U@N&7[3&LH**++LON0:]W?36[NK*RL]U:VEC!N?^";G[)%]XE_9
MA\8:AX"U_4/$G['NC:)H/P&U:^^(_P`0[JY\-Z;X>N#=Z5'K9G\3.OC2>"[(
MN7N_%ZZS=7$R@SRR+E3G?M6?\$Q/V,/VSO%>E^/_`(Z?"J74?B%I.FQZ);^/
MO"'BSQ9\/_%]SH<)D,.CZKK'@_6-(EUBPM_.E6U35$NY;..66*TF@BED1BBC
ME5K6379I-?=:WX#N[WN[KK=W^^]SJ?A7_P`$\/V./@O\#?''[./P_P#@AX<T
MSX2?$VRN+'XC:!?WFNZ[J'CF*ZM?L<DOB;Q-K.JWWB74;F.W"I9SMJR/IQ57
MT_[*XW5\IZ;_`,$)?^":5AX8U7P?=_!GQ;XBT"_A6VTNR\5_&SXR>(T\%VHU
M)-5EA^'ZZGXXGC\%R7=TFV_O]!CM-4U"UEN+*]OI[6YGBD**++LNVR_#L+:]
MFU?>S:OK?777776^NI]-^-_^"<W[*/Q&TK]F?1_&G@GQ%KEI^R)):R_`A[CX
MB>/8KWPPUC+X?EM%U2_MO$,%WXMB@/A?1$6'Q3-JT1CLD1D8/)NR?VG?^"8W
M[&/[7?CBP^*/QD^%EW)\4].L+32H/B;X"\;^-_AAX\ETRP22.PL;WQ'X"\0:
M!?7\-@LKK8/>///9)B.VFBB4)110DELETZ+IHON6B\@6FU_O?^?W]^I<^!7_
M``3N_93_`&3OA_\`%?PS\!OA(+2^^*WAC6-%\=:KK_C/Q9XB\:>/K6YTW4K>
M+0]9^('BK5]:U^RL)FU"Z2+[%<V]M8W%Y+J26[78,IX;_@E_^PY!^PM\$?&G
M@PZ1HWA;4/B5\6O%OQ/E\">&_$FN^,/#WPYT/4X['1_"/@+3/%GB3_B=^*9-
M`\.:18_VKXBU%8YM3U>ZO7BBCM8[<$HHY5=.VJO;;2^X<SNU_-=M]7:W7^ME
MV/H/]K#]C+]GO]MOP/H/PY_:.\'ZAXT\(^&O%%KXRT;3M/\`%GBOPA+;>(;.
MRO=/@O7OO"6LZ+>W*+9ZA=PFUN9Y;4^:7,/F*CK6^)/[$_[.WQ;^*GP`^-'C
MKP=J&J_$/]F&>&Y^#&LP^*_%.FP>&98'M7C-YI>G:O;:9XA&ZSM]R:_:ZBIV
M$[0S,244679?=VM;[K+[D'W_`'O\%T^1<^)/[&_P!^+?[07P<_:A\=^$]0U;
MXS_`2ROM/^&'B6#Q5XGTNRT*UU*:ZN+R.Z\.Z9JUKH&MF66\G8/K6G7SQ;E$
M1CVKCYZ_:F_X)(_L(?MB_$)_BS\:?A%?R_$N[TZ#2-8\:^!?'WCOX;ZWXCTN
MUB6WMK+Q))X*\0Z-;:UY%JBV<5[>VTFI1V:K:)>K;(D2E%.R[+75Z;^O?9;C
MNULVO1OR_P`D>P_#_P#8#_9,^%/[-WBW]DOX;?"+2?!7P+\>:9J^F>,?"^AZ
MGK\6I^)!KUM'::KJ6K^+KC5;GQ9?:Y=6\,,8UJXUF34;9(($M)X$@A6/UK]G
MG]GKX5?LL?!_P?\``CX):#=>%_ACX#M]0MO#&A7NN:WXEN+"'5=6O]<OEDUG
DQ'?ZIK%X9M2U*\N`UY?3M&)?+0K&JJI12LKWMJE;Y=OP$?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
